DAFTAR PUSTAKA

Abdelhamid,T., Samra,M., Ramadan,H., Mehessin,M., Mokhtar,N.,2011.Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study . *J Egypt Natl Canc Inst.* 23(1):17-24

Abdolrahim-Zadeh, H., Hakkakian,N., Reza Asadollahi, R., Gharesifard,B., Sarvari,J., Eskandar Kamali-Sarvestani,E., Talei, A. 2005 Interleukin-10 Promoter Polymorphisms and Breast Cancer Risk in Iranian Women. IJI : 2 ;3

Aggarwal,D., Gupta,R., Singh,S., Kudesia,M .,2011. Comparison of working formulation and REAL classification of non-Hodgkin's lymphoma: an analysis of 52 cases. *Hematology*. 16(4):195-9

Ahirwar, D., Mandhani, A., Mittal, R.D. 2009 Interleukin-10 G-1082A and C-819T polymorphisms as possible molecular markers ofurothelial bladder cancer. *Arch Med Res*.;40(2):97-102

Alizadeh, A. A., Eisen, M.B., Davis, R.E.,Ma, C., Lossos,I.S., Rosenwald, A., BoldrickJ.C., Sabet, H., Tran, T., Yu,X., Powell, J.I., Yang, L., Marti, G.E., Moore, T., Hudson,J.Jr., Lu,L., Lewis,D.B., Tibshirani, R., Sherlock, G., Chan, W.C., Greiner, T.C., Weisenburger, D.D., Armitage, J.O., Warnke, R., Levy, R., Wilson, W., Grever, M.R., Byrd, J.C., Botstein, D., Brown, P.O., Staudt, L.M. 2000. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. *Nature*. 403:503-511

Akay, O.M., Aras, B.D., Isiksoy, S., Toprak, C., Mutlu, F.S., Artan, S., Oner, U., Gulbas, Z., 2014. BCL2, BCL6, IGH, TP53, and MYC protein expression and gene rearrangements as prognostic markers in diffuse large B-cell lymphoma: a study of 44 Turkish patients. *Cancer Genet.* 207(3):87-93

Almasri, N.M., Habashneh, M.A., Khalidi, H.S., 2004. Non-Hodgkin lymphoma in Jordan. Types and patterns of 111 cases classified according to the WHO classification of hematological malignancies. *Saudi Med J* . 25(5):609–614

Ameen, R., Sajnani, K.P., Albassami, A., Refaat, S., 2010 . Frequencies of non-Hodgkin’slymphoma subtypes in Kuwait: comparisons between different ethnic groups. *Ann Hematol*;89(2):179–184

Armitage, J.O., 1997. The changing classification of non-Hodgkin lymphoma. *CA Cancer J Clin* . 47 : 323-325

Aukema, S.M., Siebert, R., Schuuring, E., van Imhoff, G.W., Kluin-Nelemans, H.C., Boerma, E.J., Kluin, P.M. 2011 Double-hit B-cell lymphomas.*Blood*;117(8):2319-31

Aydin, F., Yilmaz, M., Ozdemir, F., Kavgaci, H., Yavuz, M.N., Yavuz, A.A 2002 Correlation of serum IL-2, IL-6 and IL-10 levels with International Prognostic Index in patients with aggressive non-Hodgkin's lymphoma. *Am J Clin Oncol.*;25(6):570-2.

Bai, M., Skyrlas, A., Agnantis, N.J., Kamina, S., Tsanou, E., Grepi, C., Galani, V., Kanavaros, P., 2004. Diffuse large B-cell lymphomas with germinal center B-cell-like differentiation immunophenotypic profile are associated with high apoptotic index, high expression of the proapoptotic proteins bax, bak and bid and low expression of the antiapoptotic protein bcl-xl. *Mod Pathol*. 17(7):847-56.

Balducci, L., Hardy,C.L., Lyman,G.H.2005 Hemopoiesisand aging.*Cancer Treat Res*. ;124:109-34

Baris, D., Zahm, S.H., 2000 . Epidemiology of lymphomas. *Curr Opin Oncol* .12:383–394

Barrans, S.L ,Carter, I., Owen, R.G., Davies, .FE., Patmore, R.., Haynes AP, Morgan, G.J., Jack, A.S. 2002. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. *Blood* 99:1136-1143

Baştürk, B., Yavaşçaoğlu, I., Vuruşkan, H., Göral, G., Oktay, B., Oral, H.B. 2005 Cytokine gene polymorphisms as potential risk and protective factors in renal cell carcinoma. *Cytokine*. ;30(1):41-5.

Bornstein, S., Schmidt, M., Choonoo, G., Levin. T., Gray. J., Thomas ,C.R Jr, Wong, M., McWeeney, S. 2016 IL-10 and integrin signaling pathways are associated with head and neck cancer progression. *BMC Genomics.*;17(1):38

Belkaid, Y., 2007. Regulatory T cells and infection: a dangerous necessity. *Nat Rev Immunol*.;7:875–88.

Belluco, C., Olivieri, F., Bonafè, M., Giovagnetti, S., Mammano, E., Scalerta, R., Ambrosi, A., Franceschi, C., Nitti, D., Lise, M., 2003. -174 G>C polymorphism of interleukin 6 gene promoter affects interleukin 6 serum level in patients with colorectal cancer. *Clin Cancer Res.* ; 6:2173-6.

Bernd, H.W., Ziepert, M., Thorns. C., Klapper, W., Wacker, H.H., Hummel, M., Stein, H., Hansmann, M.L., Ott, G., Rosenwald, A., Müller-Hermelink, H.K., Barth, T.F., Möller, P.,Cogliatti, S.B., Pfreundschuh,

M., Schmitz, N., Trümper, L., Höller, S., Löffler, M., Feller, A.C., 2009. Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma – analyses of cases from two prospective randomized clinical trials. *Haematologica*. 94(11):1569-80

Bogunia-Kubik, K., Mazur, G., Wróbel, T., Kuliczkowski, K., Lange, A. 2008 Interleukin-10 gene polymorphisms influence the clinical course of non-Hodgkin's lymphoma. *Tissue Antigens.*;71(2):146-50

Brien, G., Trescol-Biemont, M.C., Bonnefoy-Bérard, N., 2007.Downregulation of Bfl-1 protein expression sensitizes malignant B cells to apoptosis. *Oncogene .26:5828–32*

Burkhardt, B., Oschlies, I., Klapper, W., Zimmermann, M., Woessmann, W., Meinhardt ,A., Landmann, E., Attarbaschi, A., Niggli, F., Schrappe, M., Reiter, A. 2011 Non-Hodgkin's lymphoma in adolescents: experiences in 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols. *Leukemia.* ;25(1):153-60.

Burkhardt, B., Zimmermann, M., Oschlies, I., Niggli, F., Mann, G., Parwaresch, R., Riehm, H., Schrappe, M., Reiter, A. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. *Br J Haematol*. 2005 Oct;131(1):39-49.

Carbone, A., Gloghini, A., Dotti, G.2008 EBV-associated lymphoproliferative disorders: classification and treatment. *Oncologist* ;13(5):577-85

Carreon, J.D., Morton, L.M., Devesa, S.S., Clarke, C.A., Gomez, S.L., Glaser, S.L., Sakoda, L.C., Linet, M.S., Wang, S.S., 2008. Incidence of lymphoid neoplasms by subtype among six Asian ethnic groups in the United States, 1996–2004. *Cancer Causes Control* ; 19: 1171–81.

Castella, A.1., Joshi, S., Raaschou, T., Mason, N., 2001. Pattern of malignant lymphoma in the United Arab Emirates--a histopathologic and immunologic study in 208 native patients. *Acta Oncol*. 40(5):660-4

Chai, S.P., Peh, S.C., Kim, L.H., Lim, M.Y., Gudum, H.R., 1999. The pattern of lymphoma in east Malaysian patients as experienced in the University Hospital, Kuala Lumpur. *Malays J Pathol*. 21(1):45-50

Chand-Bhayal, A., Krishnaveni, D., Pandu-Ranga-Rao, K., Prabhakar, B., Vidyasagar, A., Bal Murali-Krishna , B., Anita, P., Jyothy, A., Nallari, P., Venkateshwari,A., 2012 Association of Interleukin-10 Promoter Polymorphism (-1082 G/A) and Gastric Cancer in Andhra Pradesh Population of South India. *Iran J Cancer Prev* ; 3:117-123

Chang, C.C., McClintock, S., Cleveland, R.P., 2004. et al: Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. *Am J Surg Pathol* 28:464-470

Chen, Y., Han, T., Iqbal, J., Irons, R., Chan, W.C., Zhu, X., Fu, K., 2010. Diffuse large B-cell lymphoma in Chinese patients: immunophenotypic and cytogenetic analyses of 124 cases.*Am J Clin Pathol*;133(2):305-13

Chen, J., Xu-Monette, Z.Y., Deng, L., Shen, Q., Ganiraju, C., Manyam,Martinez-Lopez, A., Zhang, L., Montes-Moreno, S., Carlo Visco, C., Tzankov, A., Yin, L., Dybkaer, K., Chiu, A., Orazi, A., Zu,Y., Bhagat, G.,Kristy, L., Richards, Hsi, E.D., Choi, W.W.L,J. Han van Krieken, J.H., Huh, J., Ponzoni,M., Ferreri, A.J.M., Zhao, X., Møller,M.B.,[19] John P. Farnen,J.P., Winter, J.N., Piris, M.A., Pham, L., Young, K.H., 2015 Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma. *Oncotarget* ; 6(8): 5597–5614.

Chen, W.L., Tsai, W.C., Chao, T.Y., Sheu, L.F., Chou, J.M., Kao, W.Y., Chen, Y.C., Ho, C.L., 2010 The clinicopathological analysis of 303 cases with malignant lymphoma classified according to the World Health Organization classification system in a single institute of Taiwan. *Ann Hematol* ; 89 :53-62.

Chen, C.J., Sung, W.W., Lin, Y.M., Chen, M.K., Lee, C.H., Lee, H., Yeh, K.T., Ko, J.L 2012 Gender difference in the prognostic role of interleukin 6 in oral squamous cell carcinoma. *PloS One*. ;7(11)

Chenjiao, Y., Zili, F., Haibin, C., Ying, L., Sheng, X., Lihua, H., Wei, D., 2013. IL-10 promoter polymorphisms affect IL-10 production and associate with susceptibility to acute myeloid leukemia. *Pharmazie*. 68(3):201-6.

Chiu, B.C., Weisenburger, D.D., 2003. An update of the epidemiology of non-Hodgkin's lymphoma. *Clin Lymphoma*. 4(3):161-8

Cho, E.Y., Kim, K.H., Kim, W.S., Yoo, K.H., Koo, H.H., Ko, Y.H. 2008 The spectrum of Epstein-Barr virus-associated lymphoproliferative disease in Korea: incidence of disease entities by age groups. *Korean Med Sci.*;23(2):185-92

Choi, W.W., Weisenburger, D.D., Greiner, T.C., Piris, M.A., Banham, A.H., Delabie, J., Braziel, R.M., Geng, H., Iqbal, J., Lenz, G., Vose, J.M., Hans, C.P., Fu, K., Smith, L.M., Li, M., Liu, Z., Gascoyne, R.D., Rosenwald, A., Ott, G., Rimsza, L.M., Campo, E., Jaffe, E.S., Jaye, D.L., Staudt, L.M., Chan, W.C., 2009 A new immunostain algorithm classifies

diffuse large B-cell lymphoma into molecular subtypes with high accuracy.*Clin Cancer Res* ;15(17):5494-502

Clarke, C.A., Glaser, S.L, Gomez, S.L., Wang, S.S., Keegan, T.H., Yang, J., Chang, E.T., 2011 Lymphoid malignancies in US. Asians: incidence rate differences by birthplace and acculturation. *Cancer Epidemiol Biomarkers Prev* ; 20 : 1064-77.

Clarke, C.A., Undurraga, D.M., Harasty, P.J., Glaser, S.L., Morton, L.M., Holly, E.A., 2006 Changes in cancer registry coding for lymphoma subtypes: reliability over time and relevance for surveillance and study. *Cancer Epidemiol Biomarkers Prev* ;15:630–8

Clarke, C.A., Glaser, S.L., 2002. Changing incidence of non-Hodgkin lymphomas in the United States. *Cancer*. 94 ; 2015–2023

Cocco, P., Kazerouni, N., Zahm, S.H., 2000 Cancer mortality and environmental exposure to DDE in the United States. *Environ Health Perspect* ; 108, 1-4.

Cocco1, P., Brennan, P., Ibba1, A., 2008. de Sanjosé Llongueras S, Maynadié M, Nieters A, Becker N, M Ennas MG, Tocco MG, Boffetta P. Plasma polychlorobiphenyl and organochlorine pesticide level and risk of major lymphoma subtypes. *Occup Environ Med* 65:132-140

Cook, M.B., Dawsey, S.M., Freedman, N.D., Inskip, P.D., Wichner, S.M., Quraishi, S.M., Devesa, S.S., McGlynn, K.A.., 2009 Sex disparities in cancer incidence by period and age .*Cancer Epidemiol Biomarkers Prev* ;18(4):1174-82

Cortes, J., Kurzrock, R., 1997. Interleukin-10 in non-Hodgkin's lymphoma. *Leuk Lymphoma*. 26(3-4):251-9.

Costas, L., Casabonne, D., Benavente, Y., Becker, N., Boffetta, P., Brennan, P., Cocco, P., Foretova, L., Maynadié, M., Staines, A., Kane, E., Nieters, A., de Sanjosé, S., 2012 Reproductive factors and lymphoid neoplasms in Europe: findings from the EpiLymph case-control study. *Cancer Causes Control*.;23(1):195-206

Dai, Z.J., Wang, X.J., Zhao, Y., Ma, X.B., Kang, H.F., Min, W.L., Lin, S., Yang, P.T., Liu, X.X. 2014 Effects of interleukin-10 polymorphisms (rs1800896, rs1800871, and rs1800872) on breast cancer risk: evidence from an updated meta-analysis. *Genet Test Mol Biomarkers*.;18(6):439-45

Dai, Z-M., He, A-L., Zhang, W-G. , Liu, J. , Cao, X-M. , Chen, Y-X. , Ma, X-R., Zhao, W-H. , Zhi-Jun Dai, Z-J. 2014 Association of the four common polymorphisms in interleukin-10 (rs1800890, rs1800896,

rs1800871, and rs1800872) with non-Hodgkin's lymphoma risk: a meta-analysis. *Int J Clin Exp Med* ;7(12):4720-4733

Dang, C.V., O'Donnell, K.A., Zeller, K.I., Nguyen, T., Osthus, R.C., Li, F., 2006 The c-Myc target gene network. *Semin Cancer Biol* 16(4):253-264

Deans, C., Rose-Zerilli, M., Wigmore, S., Ross, J., Howell, M., Alan Jackson, A., Grimble, R., Fearon, K. 2006 Host Cytokine Genotype is Related to Adverse Prognosis and Systemic Inflammation in Gastro-Oesophageal Cancer. *Annals of Surgical Oncology* : 14 (2) : 329-339

de Jong, D., Balagué Ponz, O., 2011 The molecular background of aggressive B cell lymphomas as a basis for targeted therapy.*J Pathol*;223(2):274-82

De Paepe, P., Achten, R., Verhoef, G., Wlodarska, I., Stul, M., Vanhentenrijk, V., Praet, M., De Wolf-Peeters, C. 2005. Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas. *J Clin Oncol* 23:7060–8

Domingo-Domènech, E., Benavente, Y., González-Barca, E., Montalban, C., Gumà, J., Bosch, R., Wang, S.S., Lan, Q., Whitby, D., Fernández de Sevilla A., Rothman, N., de Sanjosé S., 2007. Impact of interleukin-10 polymorphisms (−1082 and −3575) on the survival of patients with lymphoid neoplasms. *Haematologica*. 92(11):1475-81

Dunleavy, K., Pittaluga, S., Czuczman, M.S., Dave, S.S., Wright, G., Grant, N., Shovlin, M., Jaffe, E.S., Janik, J.E., Staudt, L.M., Wilson, W.H., 2009 Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.*Blood* ;113(24) :6069-76

Engelhard, M., Brittinger, G., Huhn, D., Gerhartz, H.H., Meusers, P., Siegert, W., Thiel, E., Wilmanns, W., Aydemir, U., Bierwolf, S., Griesser, H.,Tiemann, M., Lennert, K.1997 Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor. *Blood.* 1997 Apr 1;89(7):2291-7

Eskdale J, Gallagher G, Verweij CL, Keijsers V,Westendorp RG, Huizinga TW. 1998 Interleukin 10 secretionin relation to human IL-10 locus haplotypes.*Proc Natl Acad Sci U S A.* ;95:9465-9470.

Feugier, P., Van Hoof A., Sebban, C., Solal-Celigny, P., Bouabdallah, R., Fermé, C., Christian, B., Lepage, E., Tilly, H., Morschhauser, F., Gaulard, P., Salles, G., Bosly, A., Gisselbrecht, C., Reyes, F., Coiffier, B., 2005. de l'Adulte Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes. *J Clin Oncol.* 20;23(18):4117-26

Fimognari, F.L., Repetto, L., Moro, L., Gianni, W., Incalzi, R.A. 2005 Age, cancer and the risk of venous thromboembolism. *Crit Rev Oncol Hemato*l.;55(3):207-12.

Fujieda. S., Lee, K., Sunaga, H., Tsuzuki, H., Ikaw,a H., Fan ,G.K., Imanaka, M., Takenaka, H., Saito, H.1999 Staining of interleukin-10 predicts clinical outcome in patients with nasopharyngeal carcinoma.*Cancer.*;85(7):1439-45.

Fu, K., Weisenburger, D.D., Choi, W.W., Perry, K.D., Smith, L.M., Shi, X., Hans, C.P., Greiner, T.C., Bierman, P.J., Bociek, R.G., Armitage, J.O., Chan, W.C., Vose, J.M., 2008 Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. *J Clin Oncol* ;26(28):4587-94.

Fujita, A., Tomita, N., Fujita, H, Motohashi, K., Hyo, R., Yamazaki, E., Hattori, M., Fujisawa, S., Kanamori, H., Ogawa, K., Motomura, S, Kodama, F., Ishigatsubo, Y. 2009 Features of primary extranodal lymphoma in Kanagawa, a human T-cell leukemia virüs type 1 nonendemic area in Japan. *Med Oncol*, 26, 49-54.

Ghimire, P., Wu, G.Y., Zhu, L. Primary gastrointestinal lymphoma. *World J Gastroenterol.* 2011;17:697–707

Glaser, S.L., Gomez, S.L., Clarke, C .A.1., Wang, S.S., Keegan, T.H., Yang, J., Chang, E.T., 2011. Lymphoid malignancies in U.S. Asians: incidence rate differences by birthplace and acculturation. *Cancer Epidemiol Biomarkers Prev*. 20:1064–1077

Gomes, M., Coelho, A., Araújo, A., Azevedo, A., Teixeira, A., L., Catarino, R., Medeiros, R., IL-6 2015 polymorphism in non-small cell lung cancer: a prognostic value? *Tumor Biol* ; 36:3679–3684

Green, T.M., Nielsen, O., Xu-Monette, Z.Y., Young, K.H., Moller, M.B., 2012. High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma. *Am J Surg Pathol*. 36 (4):612–9.

Green, M.R., Rodig, S., Juszczynski, P., Ouyang, J., Sinha, P., O'Donnell, E., Neuberg, D., Shipp, M.A., 2012. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. *Clin Cancer Res*. 18: 1611-1618.

Grivennikov, S.I., Greten, F.R., Karin, M., 2010. Immunity, inflammation, and cancer. *Cell.*140:883–899.

Guney, N., Soydinc ,H.O., Basaran, M., Bavbek, S., Derin, D., Camlica, H., Yasasever, V., Topuz, E. 2009 Serum levels of interleukin-6 and interleukin-10 in Turkish patients with aggressive non-Hodgkin's lymphoma. *Asian Pac J Cancer Prev.*;10(4):669-74.

Guo, Y., Xu, F., Lu, T., Duan, Z., Zhang, Z. 2012 Interleukin-6 signaling pathway in targeted therapy for cancer. *Cancer Treatment Reviews* ; 38 : 904–910

Gupta, M., Han, J.J., Stenson, M., Maurer, M., Wellik, L., Hu, G., Ziesmer, S., Dogan, A., Witzig, T.E., 2012. Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation. *Blood*.22;119(12):2844-53

Gurbuxani, S., Anastasi, J., Hyjek, E., 2009. Diffuse large B-cell lymphoma-more than a diffuse collection of large B cells: An entity in search of a meaningful classification.*Arch Pathol Lab Med*.133:1121–34

Gutie´rrez-García, G., Cardesa-Salzmann, T.,1 Climent, F., Gonza´lez-Barca, E.,Mercadal, S., Mate, J.L., Sancho, J.M., Arenillas, L., Serrano, S., Escoda, L.,Martínez, S., Alexandra Valera, A., Martínez, A., Jares, P., Pinyol, M., García-Herrera, A., Martínez-Trillos, A., Gine´, E.,1 Villamor, N., Campo, E., Colomo, L.,Lo´pez-Guillermo, A., 2011 Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy . *Blood* ;117(18):4836-4843)

Habermann, T.M.,Wang, S.S., Maurer, M.J., Morton, L.M., Lynch, C.F.,. Ansell,S.M.., Hartge, P.,Severson, R.K., Rothman,N., Davis,S., Susan M. Geyer,S.M., Cozen,W., Chanock, S.J., Cerhan, J.R. 2008 Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era. *Blood :* 112 ; 7

Ha, S.Y., Sung, J., Ju, H., Karube, K., Kim, S.J., Kim, W.S., Seto, M., Ko, Y.H., 2013. Epstein-Barr virus-positive nodal peripheral T cell lymphomas: clinicopathologic and gene expression profiling study. *Pathol Res Pract*. 209(7):448-54

Han, X., Kilfoy, B, Zheng T, Holford TR, Zhu C, Zhu Y, Zhang Y., 2008 Lymphoma survival patterns by WHO subtype in the United States, 1973-2003. *Cancer Causes Control*, 19, 841-58.

Hans, C.P., Weisenburger, D.D., Greiner, T.C., Gascoyne, R.D., Delabie, J., Ott, G., Müller-Hermelink, H.K., Campo, E., Braziel, R.M., Jaffe, E.S., Pan, Z., Farinha, P., Smith, L.M., Falini, B., Banham, A.H., Rosenwald, A.,

Staudt, L.M., Connors, J.M, Armitage, J.O., Chan, W.C., 2004. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. *Blood.* 103:275-282, 2004

Haralambieva, E., Pulford, K.A., Lamant, L., Pileri, S., Roncador, G., Gatter, K.C., Delsol, G., Mason, D.Y., 2000. Anaplastic large-cell lymphomas of B-cell phenotype are anaplastic lymphoma kinase (ALK) negative and belong to the spectrum of diffuse large B-cell lymphomas. *Br J Haematol*. 109;584-591

Heiskanen, M., Kähönen, M., Hurme, M., Lehtimäki, T., Mononen, N., Juonala, M., Hutri-Kähönen, N., Viikari, J., Raitakari, O., Hulkkonen, J. 2010. Polymorphism in the IL10 promoter region and early markers of atherosclerosis: the Cardiovascular Risk in Young Finns Study. *Atherosclerosis.*;208(1):190-6

Herrinton, L.J., Goldoft, M,, Schwartz ,S.M., Weiss, N.S., 1996 The incidence of non-Hodgkin's lymphoma and its histologic subtypes in Asian migrants to the United States and their descendants. *Cancer Causes Control* ; 7 : 224-30

Hirschhorn, J., N., Lohmueller, K., Byrne, E., Hirschhorn, K., A., 2002 Comprehensive review of genetic association studies. *Genet Med* ;4:45–61

Hochberg, J., Waxman, I.M., Kelly, K.M., Morris,E., Cairo,M.S. 2008 Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science. *Br J Haematol* ; 144, 24–40

Hockenbery, D., Nuñez ,G., Milliman, C., Schreiber, R.D., Korsmeyer, S.J. 1990 Bcl-2 is an inner mitochondrial membrane protein that blocked programmed cell death. *Nature* ; 348 (62299) : 334-6

Hohaus, S., Giachelia, M., Di Febo, A., Martini, M., Massini, G., Vannata, B., D'Alo,' F., Guidi, F., Greco, M., Pierconti, F., Larocca, L.M., Voso, M.T., Leone, G., 2007. Polymorphism in cytokine genes as prognostic markers in Hodgkin'slymphoma. *Ann Oncol* ;18:1376–1381

Hong, J., Park, S., Park, J., Kim, H.S., Kim, K.H., Ahn, J.Y., Rim, M.Y., Jung, M., Sym, S.J., Cho, E.K., Shin, D.B., Lee, J.H., 2011. Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy. *Leuk Lymphoma.* 52(10):1904-12.

Horn, H., Staiger, A.M., Vöhringer, M., Hay, U., Campo, E., Rosenwald, A., Ott, G., Ott ,M.M., 2015 Diffuse large B-cell lymphomas of immunoblastic

type are a major reservoir for MYC-IGH translocations. *Am J Surg Pathol.* ;39(1):61-6

Horn, H., Ziepert, M., Becher, C., Barth, T.F., Bernd, H.W., Feller, A.C., Klapper, W., Hummel, M., Stein, H., Hansmann, M.L., Schmelter, C., Möller, P., Cogliatti, S., Pfreundschuh, M., Schmitz, N., Trümper, L., Siebert, R., Loeffler, M., Rosenwald, A., Ott, G., 2013. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. *Blood* .121(12):2253-2263

Howell, W.M., Rose-Zerilli, M.J. 2007. Cytokine Gene Polymorphisms, Cancer Susceptibility, and Prognosis. *J. Nutr*. . 137 (1) : 194S-199S

Huang X, Kushekhar K, Nolte I, Kooistra W, Visser L, Bouwman I, Kouprie N, Veenstra R, van Imhoff G, Olver B, Houlston RS, Poppema S, Diepstra A, Hepkema B, van den Berg A. 2011 Multiple HLA class I and II associations in classical Hodgkin lymphoma and EBV status defined subgroups.*Blood*. ;118(19):5211-7

Huang, H.H., Xiao, F., Chen, F.Y., Wang, T., Li, J.M., Wang, J.M., Cao, J.N., Wang, C., Zou, S.H., 2012. Reassessment of the prognostic value of the International Prognostic Index and the revised International Prognostic Index in patients with diffuse large B-cell lymphoma: A multicentre study. *Exp Ther Med.* 4(3):475-480

Huang, Y., Ye, S., Cao, Y., Li, Z., Huang, J., Huang, H., Cai, M., Luo, R., Lin, T., 2012 Outcome of R-CHOP or CHOP regimen for germinal center and nongerminal centersubtypes of diffuse large B-cell lymphoma of Chinese patients. *ScientificWorldJournal.*:897178

Huang, Y.C., Liu, C.Y., Lu, H.J., Liu, H.T., Hung, M.H., Hong, Y.C., Hsiao, L.T., Gau, J.P., Liu, J.H., Hsu, H.C., Chiou, T.J., Chen, P.M., Tzeng, C.H., Yu, Y.B., 2013 Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era.*Ann Hematol* ;92(11):1513-20

Huh, J., 2012. Epidemiologic overview of malignant lymphoma. *Korean J Hematol.* 47(2): 92–104.

Hunt, K.E., Reichard, K.K. 2008 Diffuse large B-cell lymphoma.Arch Pathol Lab Med. ;132(1):118-24

Ilic´ , I., Mitrovic´, Z., Aurer, I., Basˇic´-Kinda, S., Radman, I., Ajdukovic´, R., Labar, B., Dotlic´, S., Nola, M., 2009. Lack of prognostic significance of the germinal-center phenotype in diffuse large B-cell lymphoma patients treated with CHOP-like chemotherapy with and without rituximab. *Int J Hematol*. 90:74–80

Iqbal, J., Meyer, P.N., Smith, L., Johnson, N.A., Vose, J.M., Greiner, T.C., Connors, J.M., Staudt, L.M., Rimsza, L., Jaffe, E., Rosenwald, A., Ott, G., Delabie, J., Campo, E., Braziel, R.M., Cook, J.R., Tubbs, R.R., Gascoyne, R.D., Armitage, J.O., Weisenburger, D.D., Chan, W.C., 2011. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab. *Clin Cancer Res*. 17(24):7785-95

Iqbal, J., Neppalli, V.T., Wright, G., Dave, B.J., Horsman, D.E., Rosenwald, A., Lynch, J., Hans, C.P., Weisenburger, D.D., Greiner, T.C., Gascoyne, R.D., Campo, E., Ott, G., Müller-Hermelink, H.K., Delabie, J., Jaffe, E.S., Grogan, T.M., Connors, J.M., Vose, J.M., Armitage, J.O., Staudt, L.M., Chan, W.C., 2006. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. *J Clin Oncol*. 24(6):961-8

Iqbal, J., Greiner, T.C., Patel, K., Dave, B.J., Smith, L., Ji, J., Wright, G., Sanger, W.G., Pickering, D.L., Jain, S., Horsman, D.E., Shen, Y., Fu, K., Weisenburger, D.D, Hans, C.P., Campo, E., Gascoyne, R.D., Rosenwald, A., Jaffe, E.S, Delabie, J., Rimsza, L., Ott, G., Müller-Hermelink, H.K., Connors, J.M., Vose, J.M., McKeithan, T., Staudt, L.M., Chan, W.C., 2007 Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. *Leukemia* ;21(11):2332-43.

Jaffe, E.S., Harris, N.L., Stein, H., Vardiman, J.W., editors. *Pathology and genetics of tumours of haematopoietic and lymphoid tissues.* Lyon, France: IARC Press; 2001

Janssen-Heijnen, M.L., van Spronsen, D.J., Lemmens, V.E., Houterman, S., Verheij, K.D., Coebergh, J.W., 2005 A population-based study of severity of comorbidity among patients with non-Hodgkin's lymphoma: prognostic impact independent of International Prognostic Index. *Br J Haematol*;129(5):597-606

Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., Forman, D. 2011 Global cancer statistics. *CA Cancer J Clin*.;61(2):69-90.

Johnson, N.A., Slack, G.W., Savage, K.J., Connors, J.M., Ben-Neriah, S., Rogic, S., Scott, D.W., Tan, K.L., Steidl, C., Sehn, L.H., Chan, W.C., Iqbal, J., Meyer, P.N., Lenz, G., Wright, G.,Rimsza, L.M., Valentino, C., Brunhoeber, P., Grogan, T.M., Braziel, R.M., Cook, J.R., Tubbs, R.R., Weisenburger, D,D,, Campo, E., Rosenwald, A., Ott, G., Delabie, J., Holcroft,C.,Jaffe,E.S., Staudt, L.M., Gascoyne,R.D.,2012. Concurrent expression of MYC and BCL2 in diffuse large Bcell lymphoma treated with rituximab pluscyclophosphamide, doxorubicin, vincristine, and prednisone. *J Clin Oncol.* 30(28):3452-9

Jovanović, M.P., Jaković, L., Bogdanović, A., Marković, O., Martinović ,V.C., Mihaljević, B., 2009. Poor outcome in patients with diffuse large B-cell lymphoma is associated with high percentage of bcl-2 and Ki 67-positive tumor cells. *Ca Vojnosanit Pregl.* 66(9):738-43

Kemal, Y,. Teker, F., Demirag, G., Yucel, I. 2015 Primary testicular lymphoma: a single centre experience. *Exp Oncol.*;37(3):223-6

Khatun, S., Fujimoto, J., Toyoki, H., Tamaya, T. 2003 Clinical implications of expression of ETS-1 in relation to angiogenesis in ovarian cancer. *Cancer Sci* ; 94 (9) : 769-73

Kluin, P., Schuuring, E., 2011. Molecular cytogenetics of lymphoma: where do we stand in 2010? *Histopathology*. 58(1):128–44.

Kluk, M.J., Chapuy, B., Sinha, P., Roy, A., Dal Cin, P., Neuberg, D.S., Monti, S., Pinkus, G.S., Shipp, M.A., Rodig, S.J. 2012. Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. *PLoS ONE*. 7(4):e33813

Kramer, M.H., Hermans, J., Parker, J., Krol, A.D., Kluin-Nelemans, J.C., Haak, H.L., van Groningen, K., van Krieken, J.H., de Jong, D., Kluin, P.M., 1996. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. *J Clin Oncol.* 14(7):2131-8

Krol, A.D., le Cessie, S., Snijder, S., Kluin-Nelemans, J.C., Kluin, P.M., Noordijk, E.M. 2003. Primary extranodal non-Hodgkin's lymphoma (NHL): the impact of alternative definitions tested in the Comprehensive Cancer Centre West populatin-based NHL registry. *Ann Oncol*, 14, 131-9.

Kube, D., Hua, T.D., von Bonin, F., Schoof, N., Zeynalova, S., Klöss, M., Gocht, D., Potthoff, B., Tzvetkov, M., Brockmöller, J., Löffler, M., Pfreundschuh, M., Trümper, L. 2008 Effect of interleukin-10 gene polymorphisms on clinical outcome of patients with aggressive non-Hodgkin's lymphoma: an exploratory study. *Clin Cancer Res* ;14(12):3777-84.

Kurzrock, R., 2001. Cytokine deregulation in cancer. *Biomed Pharmacother.* 55(9-10):543-7

Küppers, R., Engert, A. , Hansmann , M-L. 2012 Hodgkin Lymphoma *J Clin Invest* ;122(10):3439–3447

Lal, A., Bhurgri ,Y., Vaziri, I., Rizvi, N.B., Sadaf, A., Sartajuddin, S., Islam, M., Kumar, P., Adil, S., Kakepoto, G.N., Masood, N., Khurshed, M., Alidina, A. 2008 Extranodal non-Hodgkin's lymphomas- a

retrospective review of clinico-pathologic features and outcomes in comparison with nodal non- Hodgkin's lymphomas. *Asian Pac J Cancer Prev*, 9, 453-8.

Lemeshow, S. & David W.H.Jr, 1997. *Besar Sampel dalam Penelitian Kesehatan (terjemahan)*, Gadjahmada University Press, Yogyakarta

Laporan Tahunan Bagian Patologi Anatomi RS. Sardjito, 2014

Lee, M.Y., Tan, T.D., 2005. Clinicopathological analysis of malignant lymphoma in Taiwan, defined according to the World Health Organization classification .*Haematologica* . 90:1703-1705

Lech-Maranda, E., Baseggio, L., Bienvenu, J., Charlot, C., Berger, F., Rigal, D., Warzocha, K., Coiffier, B., Salles, G,. 2004. Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. *Blood* 103:3529-3534

Lee, M.Y., Tan, T.D., Feng, A.C, Liu, M.C. 2006 Clinicopathological analysis of 598 malignant lymphomas in Taiwan: seven-year experience in a single institution. *Am J Hematol*;81(8):568-75

Lenz, G., Wright, G., Dave, S.S., Xiao, W., Powell, J., Zhao, H., Xu, W., Tan, B., Goldschmidt, N., Iqbal, J., Vose, J., Bast, M., Fu, K., Weisenburger, D.D., Greiner, T.C., Armitage, J.O., Kyle, A., May, L., Gascoyne, R.D., Connors, J.M., Troen, G., Holte, H., Kvaloy, S., Dierickx, D., Verhoef, G., Delabie, J., Smeland, E.B., Jares, P., Martinez, A., Lopez-Guillermo, A., Montserrat, E., Campo, E., Braziel, R.M., Miller, T.P., Rimsza, L.M., Cook, J.R., Pohlman, B., Sweetenham, J., Tubbs, R.R., Fisher, R.I., Hartmann, E., Rosenwald, A., Ott, G., Muller-Hermelink, HK., Wrench, D., Lister, T.A., Jaffe, E.S., Wilson, W.H., Chan, W.C., Staudt, L.M., 2008. Stromal gene signatures in large-B-cell lymphomas. *N Engl J Med* . 359:2313–2323

Levy, Y., Brouet, J.C. 1994. Interleukin-IO prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. *J Clin Invest*. 93:424-8

Li, M., Zhang, S., Gu, F., Xiao, W., Yao, J., Chao, K., Chen, M., Li, J., Zhong, B. 2014 Clinicopathological characteristics and prognostic factors of primary gastrointestinal lymphoma: a 22-year experience from South China. *Int J Clin Exp Pathol*. ; 7(5): 2718–2728.

Li, Y., Wanga,Y, Wanga,Z., Yi,D., 2015 Shuangge M. Racial differences in three major NHL subtypes: Descriptive epidemiology *Cancer Epidemiology* ; 39 : 8–13

Liu, D., O'Day, S.J., Yang, D., Boasberg, P., Milford, R., Kristedja, T,, Groshen, S., Weber, J. 2005 Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study.*Clin Cancer Res*.;11(3):1237-46.

Lin, P., Dickason, T.J., Fayad, L.E., Lennon, P.A., Hu, P., Garcia, M., 2012. Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. *Cancer*. 118(6):1566–73

Liu, J., Song, B., Fan, T., Huang, C., Xie, C., Li, J., Zhong, W., Li, S., Yu, J. 2011 Pathological and clinical characteristics of 1,248 non-Hodgkin's lymphomas from a regional cancer hospital in Shandong, China. *Asian Pac J Cancer Prev*.;12(11):3055-61.

Llanes-Ferna´ndez, L., A´lvarez-Goyanesa, R.I. Arango-Pradoa, M. C .,Juan Manuel Alcocer-Gonza´lezb, J.M., Mojarrietaa, J.C., Pe´reza, X.E., Lo´peza,M.O.,Odioa, S.F., Camacho-Rodrı´gueza, R., Guerra-Yia, M.E.,Madrid-Marinac, V.,Tamez-Guerrab, R., Rodrı´guez-Padillab, C. 2006 Relationship between IL-10 and tumor markers in breast cancer patients. *The Breast* ; 15, 482–489

Lokesh, K.N., Sathyanarayanan, V., Kuntegowdanahalli, C.L., Suresh, T.M., Dasappa, L., Kanakasetty, G.B.2014 Primary Diffuse large B-Cell lymphoma of testis: A single centre experience and review of literature. *Urol Ann*.;6(3):231-4.

Lu, T.X., Gong, Q.X., Wang, L, Fan, L., Zhang, X.Y., Chen, Y.Y., Wang, Z., Xu,W. , Zhang, Z.H., Li, J.Y . 2015 Immunohistochemical algorithm alone is not enough for predicting the outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP. *Int J Clin Exp Pathol*.;8(1):275-86..

Lu, T.,X., Miao, Y., Wu, J.Z., Gong, Q.X., Liang, J.H., Wang, Z., Wang, L., Fan, L., Hua, D., Chen, Y.Y., Xu, W., Zhang, Z.H., Li, J.Y. 2016 The distinct clinical features and prognosis of the $CD10^{+}MUM1^{+}$ and $CD10^{-}Bcl6^{-}MUM1^{-}$ diffuse large B-cell lymphoma. Sci Rep ; 6 : 20465

Lu, X.H., Mao, G.X., Zhang, Y.Y., Chu, Y.S., Yuan, H.X., Zhu, X.Q. 2015 Association between variants of IL-8 and IL-10 genes, and efficacy of transcatheter arterial chemoembolization and subsequent prognosis in patients with liver cancer. *Eur Rev Med Pharmacol Sci*.;19(17):3218-23

Lu, C.S., Chen, J.H., Huang, T.C., Wu, Y.Y., Chang, P.Y., Dai, M.S., Chen, Y.C., Ho, C.L.2015 Diffuse large B-cell lymphoma: sites of extranodal involvement are a stronger prognostic indicator than number of extranodal sites in the rituximab era. *Leuk Lymphoma*.:56(7):2047-55

Lossos, I.S., Morgensztern, D., 2006. Prognostic biomarkers in diffuse large B-cell lymphoma. *J Clin Oncol.* 24 (6) 995-1007

Mahajan, A., Wun, T., Chew, H., White, R.H. 2014 Lymphoma and venous thromboembolism: influence on mortality. *Thromb Res.* ;133 Suppl 2:S23-8

Mandal, S., Abebe, F., Chaudhary, J., 2014. -174G/C polymorphism in the interleukin-6 promoter is differently associated with prostate cancer incidence depending on race. *Genet Mol Res*.13(1):139-51

Mao, Y., Lu, M.P., Lin, H., Zhang da, W., Liu, Y., Li, Q.D., Lv ,Z.G., Xu, J.R., Chen, R.J., Zhu, J.2013 Prognostic significance of EBV latent membrane protein 1 expression in lymphomas: evidence from 15 studies. *PLoS One*.;8(4)

Marcos-Gragera, R., Allemani, C., Tereanu, C., Marcos-Gragera, R., Allemani, C., Tereanu, C., De Angelis, R., Karjalainen-Lindsberg, M.L., Simonetti, A., Martos ,M.C., Raphaël, M., Giraldo P, Sant M; HAEMACARE Working Group 2011 Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002: results of the HAEMACARE project. *Haematologica* ;96:720–728.

Marcos-Gragera, R., Pollan, M., Chirlaque, M.D., Guma, J., Sanchez, M.J., Garau, I. 2010 Attenuation of the epidemic increase in nonHodgkin's lymphoma in Spain . *Ann Oncol*; 21 : 90-96

Markkula, A., Simonsson, M., Ingvar, C., Rose, C., Jernström, H., 2014 IL6 genotype, tumour ER-status, and treatment predicted disease-free survival in a prospective breast cancer cohort. *BMC Cancer* ; 14:759

Martelli, M., Ferreri, A.J., Agostinelli, C., Di Rocco, A., Pfreundschuh, M., Pileri, S.A., 2013 Diffuse large B-cell lymphoma. *Crit Rev Oncol Hematol*. ;87(2):146-71

Mason, D.Y., Harris, N.L., 1999. *Human Lymphoma : Clinical Implications of The REAL Classification.* Springer

Mertsoylu, H., Muallaoglu, S., Besen, A.A., Erdogdu, S., Sezer, A., Sedef, A.M., Kose, F., Arican, A., Ozyilkan, O.. 2014 Primary extranodal nonHodgkin's lymphoma: clinicopathological feature s, survival and treatment outcome intwo cancer centers of southern Turke y. *Asian Pac J Cancer Prev.* ;15(17):7207-11

Meyer, P.N., Fu, K., Greiner, T.C., Smith, L.M., Delabie, J., Gascoyne, R.D., Ott, G., Rosenwald, A., Braziel, R.M., Campo, E., Vose, J.M., Lenz, G., Staudt,L.M.,Chan,W.C,Weisenburger,D.D.,2011Immunohistochemical methods for predicting cell of origin and survival in patients withdiffuse large B-cell lymphoma treated with rituximab. *J Clin Oncol*: 10;29(2):200-7.

Mikami, S., Oya, M., Mizuno, R., Murai, M., Okado, Y. 2006 Expression of ETS-1 in human clear cell renal carcinomas : implications for angiogenesis. *Cancer Sci* ; 97 : 875-82

Miles, R.R., Raphael, M., McCarthy, K., Wotherspoon, A., Lones, M.A., Terrier-Lacombe, M.J., Patte, C., Gerrard, M., Auperin, A., Sposto, R., Davenport, V., Cairo, M.S., Perkins, S.L. 2008 Pediatric diffuse large B-cell lymphoma demonstrates a high proliferation index, frequent c-Myc protein expression, and a high incidence of germinal center subtype: Report of the French-American-British (FAB) international study group.*Pediatr Blood Cancer* ;51(3):369-74.

Moore, K.W., de Waal Malefyt, R., Coffman, R.L., O'Garra, A. Interleukin-10 and the interleukin-10 receptor Annu Rev Immunol. 2001;19:683-765

Morandi, F., Croce, M., Cangemi, G., Barco, S., Rigo, V., Carlini, B., Amoroso, L., Pistoia, V., Ferrini, S., Corrias, M.V. 2015 IL-10 and ARG-1 concentrations in bone marrow and peripheral blood of metastatic neuroblastoma patients do not associate with clinical outcome.*J Immunol Res*.;:718975

Morton, L.M., Wang, S.S., Devesa, S.S., Hartge, P., Weisenburger, D.D., Linet, M.S. 2006 Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. *Blood* 2006; 107, 265–76.

Motoyama, S., Miura, M., , Hinai, Y., Maruyama, K., Usami,S., Yoshino, K., Toshinobu Nakatsu, T., Saito, H., Minamiya,Y., Ogawa, J. 2011 Interleukin-2 2330T[G Genetic Polymorphism Associates with Prognosis Following Surgery for Thoracic Esophageal Squamous Cell Cancer . *Ann Surg Oncol* : 18:1995–2002

Müller, A.M.S., Ihorst, G., Mertelsmann, R., Engelhardt, M., 2005. Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology. *Annals of Hematology* . 84 : 1-12

Ngo, L., Hee, S.W., Lim, L.C., Tao, M., Quek, R., Yap, S.P., Loong, E.L., Sng, I., Hwan-Cheong, T.L., Ang, M.K., Ngeow, J, Tham, C.K., Tan, M.H., Lim, S.T. 2008 Prognostic factors in patients with diffuse large B cell lymphoma: Before and after the introduction of rituximab. *Leuk Lymphoma*.;49(3):462-9.

Nakashima J., Tachibana M., Horiguchi Y., Oya M., Ohigashi T., Asakura H., Murai M., 2000 Serum interleukin 6 as a prognostic factor in patients with prostate cancer. *Clin. Cancer Res* ; 6: 2702-2706

Nielsen, K.R., Steffensen, R., Bendtsen, M.D., Rodrigo-Domingo, M., Baech, J., Haunstrup, T.M., Bergkvist, K.S, Schmitz, A., Boedker, J.S., Johansen, P., Dybkaeær, K., Boeøgsted, M., Johnsen, H.E. 2015 Inherited Inflammatory Response Genes Are Associated with B-Cell Non-Hodgkin's Lymphoma Risk and Survival. *PLoS One*. 8;10(10)

Nyman H, Jerkeman M, Karjalainen-Lindsberg ML, Banham AH, Enblad G, Leppä S. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas *Eur J Haematol*. 2009 May;82(5):364-72

Obermann, E.C., Csato, M., Dirnhofer, S., Tzankov, A. 2009 BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma.*J Clin Pathol*. ;62(10):903-7

Ohshima, K., Kawasaki, C., Muta, H., Muta, K., Deyev, V., Haraoka, S., Suzumiya, J., Podack, E.R., Kikuchi, M., 2001. CD10 and Bcl10 expression in diffuse large B-cell lymphoma: CD10 is a marker of improved prognosis. *Histopathology*. 2001 39(2):156-62

Oschlies, I., Klapper, W., Zimmermann, M., Krams, M., Wacker, H.H., Burkhardt, B., Harder, L., Siebert, R., Reiter, A., Parwaresch, R. 2006 Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial. *Blood*. ;107(10):4047-52.

Ott, G., Ziepert, M., Klapper, W., Horn, H., Szczepanowski, M., Bernd, H.W., Thorns, C., Feller, A.C., Lenze, D., Hummel, M., Stein, H., Müller-Hermelink, H.K., Frank, M., Hansmann, M.L., Barth, T.F., Möller, P., Cogliatti, S., Pfreundschuh, M., Schmitz, N., Trümper, L., Loeffler, M., Rosenwald, A., 2010. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. *Blood*. 116(23):4916-25.

Ozdemir, F., Aydin, F., Yilmaz, M., Kavgaci, H., Bektas, O., Yavuz, M.N., Yavuz, A.A., 2004. The effects of IL-2, IL-6 and IL-10 levels on prognosis in patients with aggressive Non-Hodgkin's Lymphoma (NHL). *Exp Clin Cancer Res.* 23(3):485-8.

Park, H.J., Park, E.H., Jung, K.W., Kong, H.J., Won, Y.J., Lee, J.Y., Yoon, J.H., Park, B.K., Lee, H., Eom, H.S., Park, S. 2012 Statistics of hematologic malignancies in Korea: incidence, prevalence and survival rates from 1999 to 2008. *Korean J Hematol* ; 47(1): 28–38

Park YH, Sohn SK, Kim JG, Lee MH, Song HS, Kim MK, Jung JS, Lee JJ, Kim HJ, Kim DH.2009 Interaction between BCL2 and interleukin-10 gene polymorphisms alter outcomes of diffuse large B-cell lymphoma following rituximab plus CHOP chemotherapy.*Clin Cancer Res*. ;15(6):2107-15.

Parkin, D.M., 2004. International variation. *Oncogene*. 23:6329–634

Pehlivan, M., Sahin, H.H., Pehlivan, S., Ozdilli, K., Kaynar, L., Oguz, F.S., Sever, T., Yilmaz, M., Eser, B., Ogret, Y.D., Kis, C., Okan, V., Cetin, M., Carin, M.2014 Prognostic importance of single-nucleotide polymorphisms in IL-6, IL-10, TGF-β1, IFN-γ, and TNF-α genes in chronic phase chronic myeloid leukemia. *Genet Test Mol Biomarkers.* ;18(6):403-9.

Pfreundschuh, M. 2010 How I treat elderly patients with diffuse large B-cell lymphoma. *Blood* ; 116 (24) : 5103-5110

Reksodiputro, A. Y., Indonesian Lymphoma Study Group . 2015 Multicentre Epidemiology and Survival Study of B Cell Non Hodgkin Lymphoma Patients In Indonesia . *J Blood Disorders Transf* , 6:2

Richiardi, L., De Marco, L., Gillio-Tos, A., Merletti, F., Fiano, V., Palli, D., Masala, G., Agnoli, C., Tagliabue, G., Panico, S., Mattiello, A., Tumino, R., Frasca, G., Vineis, P.,Sacerdote, C., 2010. Persistent infection by HCV and EBV in peripheral blood mononuclear cells and risk of non-Hodgkin's lymphoma. *Cancer Epidemiol.* 34(6):709-12.

Reber R, Banz Y, Garamvölgyi E, Perren A, Novak U. 2013 Determination of the molecular subtypes of diffuse large B-cell lymphomas using immunohistochemistry: a case series from the Inselspital, Bern, and a critical appraisal of this determination in Switzerland. *Swiss Med Wkly.* 2013 18;143:w1374

Rothman, N., Skibola, C.F., Wang, S.S., Morgan, G., Lan, Q., Smith, M.T., Spinelli, J.J., Willett, E., De Sanjose, S., Cocco, P., Berndt, S.I., Brennan, P., Brooks-Wilson, A.,Wacholder, S., Becker, N., Hartge, P., Zheng, T., Roman, E., Holly, E.A., Boffetta, P., Armstrong, B., Cozen, W., Linet, M., Bosch, F.X., Ennas, M.G., Holford, T.R., Gallagher, R.P., Rollinson, S., Bracci, P.M., Cerhan, J.R., Whitby, D., Moore, P.S., Leaderer, B., Lai, A., Spink, C., Davis, S., Bosch, R., Scarpa, A., Zhang, Y., Severson, R.K., Yeager, M., Chanock, S., Nieters, A., 2006. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. *Lancet Oncol*. 7(1):27-38.

Sahni, C.S., Desai, S.B., 2007. Distribution and clinicopathologic characteristics of non-Hodgkin's lymphoma in India: a study of 935 cases using WHO

classification of lymphoid neoplasms (2000). *Leuk Lymphoma*. 48(1):122-33

Salar, A., Fernández de Sevilla, A., Romagosa, V., Domingo-Claros, A., González-Barca, E., Pera, J., Climent, J., Grañena, A., 1998. Diffuse large B-cell lymphoma: is morphologic subdivision useful in clinical management? *Eur J Haematol*. 60(3):202-8.

Sarkozy, C., Coiffier, B., 2013 Diffuse large B-cell lymphoma in the elderly: a review of potential difficulties. *Clin Cancer Res* ;19(7):1660-9.

Sato, T., Terai, M., Tamura, Y., Alexeev, V., Mastrangelo, M., J., Selvan, S., R. , 2011 Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. *Immunol Res* ; 51:170–182

Savage, K.J., Johnson, N.A., Ben-Neriah, S., Connors, J.M., Sehn, L.H., Farinha, P., Horsman, D.E., Gascoyne, R.D., 2009. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. *Blood*. 114 : 3533-3537

Schoof ,N., Franklin, J., Fürst, R., Zander, T., von Bonin, F., Peyrade, F., Trümper, L., Diehl, V., Engert, A., Kube, D., Re, D, 2013 . Interleukin-10 gene polymorphisms are associated with freedom from treatment failure for patients with Hodgkin lymphoma.*Oncologist;*18(1):80-9.

Schoof ,N., von Bonin, F., König, I.R., Mössner, R., Krüger, U., Reich, K., Berking, C., Volkenandt, M., Ziegler, A., Böckmann, L., Kuschal, C., Thoms, K.M., Kube, D., Emmert, S. 2009 Distal and proximal interleukin (IL)-10 promoter polymorphisms associated with risk of cutaneous melanoma development: a case--control study.*Genes Immun*. ;10(6):586-90

Sehn, L.H., Berry, B., Chhanabhai, M., Fitzgerald,C., Gill, K., Hoskins,P., Klasa,R., Savage,K.J., Tamara ,T., 2007 Sutherland,J., Gascoyne,R.D., Connors, J.M.. 2007 The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard ipi for patients with diffuse large B-cell lymphoma treated with R-CHOP. *Blood* ; 109:1857–1861

Sharma A, Rajappa M, Saxena A, Sharma M. 2007 Cytokine profile in Indian women with cervical intraepithelial neoplasia and cancer cervix. *Int J Gynecol Cancer*. ;17(4):879-85

Sharma, R., Zucknick, M., London, R., Marina Kacevska, M., Liddle, C., Clarke, S.J. 2008. Systemic Inflammatory Response Predicts Prognosis in Patients with Advanced-Stage Colorectal Cancer 2008. *Clinical Colorectal Cancer*, : 7 ;(5)331-337

Sharma, M., Mannan, R., Madhukar, M., Navani, S., Manjari, M., Bhasin, T.S., Gill, K.S.2014Immunohistochemical (IHC) Analysis of NonHodgkin's Lymph oma (NHL) Spectrum According to WHO/REAL Classification: A Single Centre Experience from Punjab, India. *Clin Diagn Res.* ;8(1):46-9

Shiels, M.S., Engels, E.A., Linet, M.S., Clarke, C.A., Li, J., Hall, H.I., Hartge, P., Morton, L.M. 2013 The epidemic of non-Hodgkin lymphoma in the United States: disentangling the effect of HIV, 1992-2009. *Cancer Epidemiol Biomarkers Prev*.;22(6):1069-78.

Shiozawa,E., YamochiOnizuka,T., Takimoto,M. ,Ota,H., 2007 The GCB subtype of diffuse large Bcell lymphoma is less frequent in Asi an countries. *Leuk Res*. ;31(11):1579-83.

Shih, C.M., Lee, Y.L., Chiou, H.L., Hsu, W.F., Chen, W.E., Chou, M.C., Lin, L.Y. 2005 The involvement of genetic polymorphism of IL-10 promoter in non-small cell lung cancer. *Lung Cancer.* ;50(3):291-7

Shipp, M.A., 1994. Prognostic factors in aggressive non-Hodgkin's lymphoma: who has ' high-risk' disease? *Blood*. 83:1165–1173.

Shipp, M.A., Ross, K.N., Tamayo, P., Weng, A.P., Kutok, J.L., Aguiar, R.C., Gaasenbeek, M., Angelo, M., Reich, M., Pinkus, G.S., Ray, T.S., Koval, M.A., Last, K.W., Norton, A., Lister, T.A., Mesirov, J., Neuberg, D.S., Lander, E.S., Aster, J.C., Golub, T.R., 2002. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. *Nat Med* . 8:68-74

Siasios, I., Fotiadou, A., Fotakopoulos, G., Ioannou, M., Anagnostopoulos, V., Fountas, K. 2015 Primary Diffuse Large B-Cell Lymphoma of Central Nervous System: Is Still Surgery an Unorthodox Treatment? *J Clin Med Res.*;7(12):1007-12

Silvani A., Ferrari G., Paonessa G., Toniatti C., Parmiani G., Colombo M. P., 1995 Down-regulation of interleukin 6 receptor α chain in interleukin 6 transduced melanoma cells causes selective resistance to interleukin 6 but not to oncostatin M. *Cancer Res: 55: 2200-2205*

Singh, D., Kumar, .L, Goyal, H. 2003 Primary extranodal non- Hodgkin's lymphoma in northern India. *Proc Am Soc Clin Oncol*, 22, 2457

Slack, G.W., Gascoyne, R.D., 2011. MYC and aggressive B-cell lymphomas. *Adv Anat Pathol.* 18(3):219–28

Sjo¨, L.D., Poulsen, C.B., Hansen, M., Møller, M.B., Ralfkiaer, E., 2007. Profiling of diffuse large B-cell lymphoma by immunohistochemistry: identification of prognostic subgroups. *Eur J Haematol*.79:501–7.

Soria, J.C., Moon, C., Kemp, B.L., Liu, D.D., Feng, L., Tang, X., Chang, Y.S., Mao, L., Khuri, F.R. 2003 Lack of interleukin-10 expression could predict poor outcome in patients with stage I non-small cell lung cancer. *Clin Cancer Res.*;9(5):1785-91.

Stasi, R., Zinzani, L., Galieni, P., Lauta, V.M., Damasio, E., Dispensa, E., Dammacco, F., Tura, S., Papa, G.1994 Detection of soluble interleukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin's lymphoma. Identification ofa subset at high risk of treatment f ailure. *Cancer.* ;74(6):1792-800

Sukpanichnant, S., 2004. Analysis of 1983 cases of malignant lymphoma in Thailand according to the World Health Organization classification. *Hum Pathol.* 35(2):224-30.

Sun, J., Yang, Q., Lu, Z., He, M., Gao, L., Zhu, M., Sun, L., Wei, L., Li, M., Liu, C., Zheng, J., Liu, W., Li, G., Chen, J., 2012. Distribution of Lymphoid Neoplasms in China Analysis of 4,638 Cases According to the World Health Organization Classification American. *J Clin Pathol*. 138 : 429-434

Swerdlow, SH., 2013. Lymphoma classification and the tools of our trade: an introduction to the 2012 USCAP Long Course. *Mod. Pathol* 26 : S1–S14

Tai, W.M., Tang, P.L., Koo, Y.X., Hou,X., Tay,K.W., Quek,R., Tao,M., Lim,S.T. 2010 Do We Have the Right Prognostic Index for Diffuse Large B cell Lymphoma (DLBCL) in the Era of Rituximab? *Proceeding of Singapore Healthcare* : 19 (1)

Tapia, G., Lopez, R., Munoz-Marmol, A.M., Mate, J.L., Sanz, C., Marginet, R., 2011. Immunohistochemical detection of MYC protein correlates with MYC gene status in aggressive B cell lymphomas. *Histopathology*. 59(4):672–8.

Tarantul, V.Z., 2006 Virus-associated lymphomagenesis. *Int J Biomed Sci*. 2(2):101- 13

Taylor, C.R, Hartsock, R.J. 2011. Classifications of lymphoma; reflections of time and technology. *Virchows Arch*. 458(6):637-4

The International Non-Hodgkin's Lymphoma Prognostic Factors Project., 1993. A predictive model for aggressive non-Hodgkin's lymphoma. *N Engl J Med*. 329:987–994

Thieblemont, C., Briere, J., Mounier, N., Voelker, H.U., Cuccuini, W., Hirchaud, E., Rosenwald, A., Jack, A., Sundstrom, C., Cogliatti, S., Trougouboff, P., Boudova, L., Ysebaert, L., Soulier, J., Chevalier, C., Bron, D.,

Schmitz, N., Gaulard, P., Houlgatte, R., Gisselbrecht, C., 2011. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. *J Clin Oncol*. 29(31):4079-4087

Thieblemont, C., Coiffier, B., 2007 Lymphoma in older patients. *J Clin Oncol*. ;25(14):1916-23

Tomita N. 2011 BCL2 and MYC dual-hit lymphoma/leukemia. *J Clin Exp Hematop*.;51(1):7-12

Trikha, M., Corringham, R., Klein, B., Rossi, J-F., 2003 Targeted anti interleukin-6 monoclonal antibody therapy for cancer : A review of the rationale and clinical evidence. *Clin Cancer Res*; 9 : 4653-4665

Turner, D.M, Williams, D.M., Sankaran, D., Lazarus, M., Sinnott, P.J., Hutchinson, I.V.1997 An investigation of polymorphism in the interleukin-10 gene promoter. *Eur J Immunogenet.* ;24(1):1-8

Uskudar, T.H., Gulbas, Z., Bal, C., 2014. Serum levels of cytokines and prevalence of autoantibodies in lymphoma patients and their prognostic value. *BUON*. 19(1):191-7.

Vaidya, R., Witzig, T.E., 2014. Prognostic Factors For Diffuse Large B Cell Lymphoma In the R(X)CHOP Era. *Ann Oncol.* Mar 13

Veelken, H., Vik Dannheim, S., Schulte Moenting, J., Martens, U.M., Finke, J., Schmitt-Graeff, A., 2007. Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy. *Ann Oncol*. 18:931–9.

Vinod, C., Jyothy, A., Vijay Kumar, M., Raman, R.R, Nallari, P., Venkateshwari A.2015 A Common SNP of IL-10 (-1082A/G) is Associated With Increased Risk of Premenopausal Breast Cancer in South Indian Women. *Iran J Cancer Prev.* ;8(4):e3434.

Visco, C., Tzankov, A., Xu-Monette, Z.Y., Miranda, R.N., Tai, Y.C., Li, Y., Liu, W.M., d'Amore, E.S., Li, Y., Montes-Moreno, S., Dybkær, K., Chiu, A., Orazi, A., Zu, Y., Bhagat, G., Wang, H.Y., Dunphy, C.H., His, E.D., Zhao, X.F., Choi. W.W., Zhao, X., van Krieken J.H., Huang, Q., Ai, W., O'Neill, S., Ponzoni, M., Ferreri, A.J., Kahl, B.S., Winter, J.N., Go, R.S., Dirnhofer, S., Piris, M.A., Møller, M.B., Wu, L., Medeiros, L.J., Young, K.H., 2013 Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study.*Haematologica* ;98(2):255-63

Wang, H., Wang, L., Wuxiao, Z., Huang, H., Jiang, W., Li, Z., Lu, Y., Xia, Z. 2015 Increased serum levels of interleukin-10 predict poor prognosis in extranodal natural killer/T-cell lymphoma patients receiving asparaginase-based chemotherapy. *Onco Targets Ther.* 14;8:2589-99.

Wang, J., Shi, Y., Cao, Q., Qin, C., Zhu, J., Chen, J., Yin, C., 2012. The interleukin-10-1082 promoter polymorphism and cancer risk: a meta-analysis. *Mutagenesis.* 27 (3): 305-312

Wang, S.S., Cozen, W., Cerhan, J.R., Colt, J.S., Morton, L.M., Engels, E.A., Davis, S., Severson, R.K., Rothman, N., Chanock, S.J., Hartge, P., 2007. Immune mechanisms in non-Hodgkin lymphoma: joint effects of the TNF G308A and IL10 T3575A polymorphisms with non-Hodgkin lymphoma risk factors. *Cancer Res.* 67: 5042–5054

Winter, J.N., Weller, E.A., Horning, S.J., Krajewska, M., Variakojis, D., Habermann, T.M., Fisher, R.I., Kurtin, P.J., Macon, W.R., Chhanabhai, M., Felgar, R.E., Hsi, E.D., Medeiros, L.J., Weick, J.K., Reed, J.C., Gascoyne, R.D.,2006 Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. *Blood*. 2006 Jun 1; 107(11): 4207–4213.

Weisenburger, D.D., Savage, K.J., Harris, N.L. , Gascoyne, R.D., Jaffe, E.S., MacLennan, K.A., Rüdiger, T., Pileri, S., Nakamura, S., Nathwani, B., Campo, E., Berger, F., Coiffier, B., Kim, W.S., Holte, H., Federico, M., Au, W.Y., Tobinai, K., Armitage, J.O., Vose, J.M., 2011. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. *Blood*. 117(12):3402–3408

Westin, J.R., Fayad, L.E., 2009 Beyond R-CHOP and the IPI in large-cell lymphoma: molecular markers as an opportunity for stratification. *Curr Hematol Malig Rep. ;4(4):218-24*

Wilson, W.H., Teruya-Feldstein, J., Fest, T., Harris, C., Steinberg, S.M., Jaffe, E.S., Raffeld, M., 1997. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. *Blood.* 89(2):601-9.

Xia, Z.G., Xu, Z.Z., Zhao, W.L., Zhao, S.Q., Ding, F., Chen, Y., Chen, Q.S., Zheng,Y., Zhu,Q., Hu,J.P., Shen,Z.X., Li,J.M.,2010The prognostic value of immunohistochemical subtyping in Chinese patients with de novo diffuse large B-cell lymphoma undergoing CHOP or R-CHOP treatment. *Ann Hematol.*;89(2):171-7.

Xiu, B., Lin, Y., Grote, D.M., Ziesmer, S.C., Gustafson, M.P., Maas, M.L., Zhang, Z., Dietz, A.B., Porrata, LF., Novak, A.J., Liang, A.B., Yang, Z.Z., Ansell, S.M. 2015 IL-10 induces the development of

immunosuppressive CD14(+)HLA-DR(low/-) monocytes in B-cell non-Hodgkin lymphoma. *Blood Cancer J.* ;5:e328

Yu, K.D., Chen, A.X., Yang, C., Fan, L., Huang, A.J., Shao, Z.M. 2012 The associations between two polymorphisms in the interleukin-10 gene promoter and breast cancer risk. *Breast Cancer Res Treat.*;131(1):27-31.

Yang, Q.P., Zhang, W.Y., Yu, J.B, Zhao, S., Xu, H., Wang, W.Y., Bi, C.F., Zuo, Z, Wang, X.Q., Huang, J., Dai, L., Liu, W.P. 2011 Subtype distribution of lymphomas in southwest china: analysis of 6,382 cases using WHO classification in a single institution. *Diagn Pathol.*: 6, 77.

Yhim, H.Y., Kim, J.S., Kang, H.J., Kim, S.J., Kim, W.S., Choi, C.W., Eom, H.S., Kim, J.A., Lee, J.H., Won, J.H., Shim, H., Huh, J., Lee, D.H., Suh, C., Kwak, J.Y.2012 Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy. *Int J Cancer*. ;131(1):235-43

Yoon, S.O., Jeon, Y.K., Paik, J.H., Kim, W.Y., Kim, Y.A., Kim, J.E., Kim, C.W., 2008. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type. *Histopathology*. 53(2):205-217.

Yoon, S.O., Suh, C., Lee, D.H., Chi, H.S., Park, C.J., Jang, S.S., Shin, H.R., Park, B.H., Huh, J. 2010 Distribution of lymphoid neoplasms in the Republic of Korea: analysis of 5318 cases according to the World Health Organization classification. *Am J Hematol.*;85(10):760-4

Ziepert, M., Hasenclever, D., Kuhnt, E., Glass,B., Schmitz, N., Michael Pfreundschuh, M., Loeffler, M., 2010 Standard International Prognostic Index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. *J Clin Oncol* : 28:2373–2380

Zhang, Y.M., Zhou, X.C., Xu, Z., Tang, C. 2012 Meta-analysis of epidemiological studies of association of two polymorphisms in the interleukin-10 gene promoter and colorectal cancer risk. *Genet Mol Res*.;11(3):3389-97

Zhang, T., Xie, S., Zhu, J.H., Li, Q.W., He, J., Zeng, A.P. 2015 Association of IL10 -
819C>T and592C>A Polymorphisms with NonHodgkin LymphomaSusc eptibility: Evidence from Published Studies. *J Cancer*.;6(8):709-16.